These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7700402)

  • 21. Clinical trials and tribulations. Cholesterol veers off script.
    Couzin J
    Science; 2008 Oct; 322(5899):220-3. PubMed ID: 18845747
    [No Abstract]   [Full Text] [Related]  

  • 22. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National Cholesterol Education Panel III guidelines performance role in preventing myocardial infarction in a large cohort without a history of coronary artery disease: Korea Acute Myocardial Infarction Registry study.
    Yoon YE; Rivera JJ; Kwon DA; Chae IH; Jeong MH; Rha SW; Blumenthal RS; Nasir K; Chang HJ;
    Prev Cardiol; 2009; 12(2):109-13. PubMed ID: 19476585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
    Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto AM; Whitney E; Stein EA; Shapiro DR; Clearfield M; Weis S; Jou JY; Langendörfer A; Beere PA; Watson DJ; Downs JR; de Cani JS
    Eur Heart J; 2000 Oct; 21(19):1627-33. PubMed ID: 10988016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesterol lowering drugs.
    Amarasingham R
    N Z Med J; 1990 Mar; 103(886):138. PubMed ID: 2181355
    [No Abstract]   [Full Text] [Related]  

  • 29. Cholesterol lowering drugs.
    N Z Med J; 1990 Apr; 103(888):189. PubMed ID: 2369454
    [No Abstract]   [Full Text] [Related]  

  • 30. [Polyphepan (lignin) as an hypocholesteremic agent].
    Frolkis AV; Abramzon MA; Kislova GD; Levanova VP
    Klin Med (Mosk); 1987 Jul; 65(7):48-52. PubMed ID: 3312799
    [No Abstract]   [Full Text] [Related]  

  • 31. Cholesterol-lowering and coronary atherosclerosis: good news and bad news.
    Kreisberg RA
    Am J Med; 1996 Nov; 101(5):455-8. PubMed ID: 8948266
    [No Abstract]   [Full Text] [Related]  

  • 32. When very high cholesterol runs in the family. More than 600,000 Americans have an inherited condition that can cause heart attacks at an early age.
    Harv Heart Lett; 2014 May; 24(9):4. PubMed ID: 25151667
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cholesterol and coronary sclerosis].
    Immich H
    Versicherungsmedizin; 1997 Jun; 49(3):86-8. PubMed ID: 9273772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [One more (conclusive?) confirmation of ineffectiveness of antioxidant vitamins for prevention of coronary heart disease].
    Gratsiansky NA
    Kardiologiia; 2002; 42(2):85-6. PubMed ID: 12494214
    [No Abstract]   [Full Text] [Related]  

  • 35. Future cardiovascular end point studies: where will the research take us?
    LaRosa JC
    Am J Cardiol; 1999 Aug; 84(4):454-8. PubMed ID: 10468086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical evaluation of anticholesteremic agents].
    Kimura T; Kudo H
    Naika; 1968 Mar; 21(3):535-43. PubMed ID: 5685635
    [No Abstract]   [Full Text] [Related]  

  • 37. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels.
    Sacks FM; Rouleau JL; Moye LA; Pfeffer MA; Warnica JW; Arnold JM; Nash DT; Brown LE; Sestier F; Rutherford J
    Am J Cardiol; 1995 Mar; 75(8):621-3. PubMed ID: 7887392
    [No Abstract]   [Full Text] [Related]  

  • 38. CAD-prevention--a perspective.
    Maisch B; Shepherd J
    Herz; 1999 Feb; 24(1):1-2. PubMed ID: 10093007
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasma cholesterol and coronary artery disease: how big a heartache?
    Lyn PC
    Med J Malaysia; 1987 Mar; 42(1):22-30. PubMed ID: 3323859
    [No Abstract]   [Full Text] [Related]  

  • 40. Over-the-counter statin medications: emerging opportunities for RDs.
    Kris-Etherton P; Pearson TA
    J Am Diet Assoc; 2000 Oct; 100(10):1126, 1128,1130. PubMed ID: 11183742
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.